Delivery of recombinant proteins via the cerebrospinal fluid as a therapy option for neurodegenerative lysosomal storage diseases

International Journal of Clinical Pharmacology and Therapeutics

Volumn 47, Issue SUPPL. 1, 2009, Pages

  Hemsley, K M ^a   Hopwood, J J ^a  

^a WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

Animal models; Cerebrospinal fluid; Enzyme replacement therapy; Lysosomal storage diseases; Neuropathology

Indexed keywords

LYSOSOMAL PROTEINS; PROTEIN; RECOMBINANT PROTEIN;

ANIMAL; DEGENERATIVE DISEASE; DISEASE MODEL; ENZYME REPLACEMENT; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRASPINAL DRUG ADMINISTRATION; LYSOSOME STORAGE DISEASE; METABOLISM; METHODOLOGY; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME REPLACEMENT THERAPY; HUMANS; INJECTIONS, INTRAVENTRICULAR; INJECTIONS, SPINAL; LYSOSOMAL STORAGE DISEASES; NEURODEGENERATIVE DISEASES; PROTEINS; RECOMBINANT PROTEINS;

EID: 77649195183     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/cpp47118     Document Type: Conference Paper

References (38)

1. Auclair D, Finne J, Walkley S, Nielsen T, Fuller M, Cheng SH. Combined intravenous and intrathecal injections of rhASB in mucopolysaccharidosis VI cats. Poster #59, 10th International Symposium on Mucopolysaccharidoses and Related Diseases. Vancouver, Canada. 2008 (abstract).
2. Boviatsis EJ, Kouyialis AT, Korfias S, Sakas DE. Functional outcome of intrathecal baclofen administration for severe spasticity. Clin Neurol Neurosurg. 2005; 107: 289-295. (Pubitemid 40693504)
3. Chang M, Cooper JD, Sleat DE, Cheng SH, Dodge JC, Passini MA et al. Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis. Mol Ther. 2008; 16: 649-656. (Pubitemid 351426165)
4. Crawley AC, Marshall N, Hemsley KM, Hucker N, King B, Rozek T et al. Intra-CSF delivery of recombinant human sulphamidase to young MPS IIIA Huntaway dogs. Presented at the 10th International Symposium on Mucopolysaccharidoses and Related Diseases. Vancouver, Canada. 2008 (abstract).
5. Dickson P, McEntee M, Vogler C, Le S, Levy B, Peinovich M et al. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab. 2007; 91: 61-68. (Pubitemid 46550919)
6. Dickson P, Peinovich M, McEntee M, Lester T, Le S, Krieger A et al. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J Clin Invest. 2008; 118: 2868-2876.
7. Escolar ML, Poe MD, Provenzale JM, Richards KC, Allison J, Wood S et al. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease.N Engl J Med. 2005; 352: 2069-2081. (Pubitemid 40664308)
8. Gilmartin R, Bruce D, Storrs BB, Abbott R, Krach L, Ward J et al. Intrathecal baclofen for management of spastic cerebral palsy: multicenter trial. J Child Neurol. 2000; 15: 71-77. (Pubitemid 30139867)
9. Gliddon BL, Yogalingam G, Hopwood JJ. Purification and characterization of recombinant murine sulfamidase. Mol Genet Metab. 2004; 83: 239-245. (Pubitemid 39473066)
10. Grubb JH, Vogler C, Levy B, Galvin N, Tan Y, Sly WS. Chemically modified β-glucuronidase crosses bloodbrain barrier and clears neuronal storage in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA. 2008; 105: 2616-2621. (Pubitemid 351520562)
11. Harmatz P, Ketteridge D, Giugliani R, Guffon N, Leão Teles E, Miranda MCet al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a Phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005; 115: 681-689.
12. Haskins M, Walkley S, Rhodes J, O'Donnell P, Bryan C, Ellinwood NM. Intrathecal enzyme therapy in mucopolysaccharidosis I cats reduces storage throughout the brain. Poster 2234/W. Presented at the Annual Meeting of The American Society of Human Genetics. San Diego, CA, USA. 2007 (abstract): http://www. ashg.org/cgi-bin/ashg07s/ashg07.
13. Hemsley KM, King B, Hopwood JJ. Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice. Mol Genet Metab. 2007; 90: 313-328. (Pubitemid 46241904)
14. Hemsley KM, Beard H, King BM, Hopwood JJ. Effect of high dose, repeated intra-CSF injection of sulphamidase on neuropathology in MPS IIIA mice. Genes Brain Behav. 2008; 7: 740-753.
15. Hemsley KM, Luck AJ, Crawley AC, Hassiotis S, Beard H, King B et al. Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease. Eur J Neurosci. 2009a; 29: 1197-1214.
16. Hemsley KM, Norman EJ, Crawley AC, Auclair D, King B, Fuller M et al. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs: a proof of principle study. Mol Genet Metab. 2009b;
17. [In Press]. Hoogerbrugge PM, Brouwer OF, Bordigoni P, Ringden O, Kapaun P, Ortega JJ et al. Allogeneic bone marrow transplantation for lysosomal storage diseases. The European Group for Bone Marrow Transplantation. Lancet. 1995; 345: 1398-1402.
18. Hopwood JJ, Vellodi A, Scott HS, Morris CP, Litjens T, Clements PRet al. Long-term clinical progress in bone marrow transplanted mucopolysaccharidosis Type I patients with a defined genotype. J Inherit Metab Dis. 1993; 16: 1024-1033. (Pubitemid 23349986)
19. Kakavanos R, Turner CT, Hopwood JJ, Kakkis ED, Brooks DA. Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I. Lancet. 2003; 361: 1608-1613. (Pubitemid 36578998)
20. Kakkis E, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med. 2001; 344: 182-188. (Pubitemid 32064139)
21. Kakkis E, McEntee M, Vogler C, Le S, Levy B, Belichenko P et al. Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab. 2004; 83: 163-174. (Pubitemid 39328075)
22. Kondagari GS, King BM, Hemsley KM, Hopwood JJ, Taylor R. Intrathecal enzyme infusion therapy in canine fucosidosis. Presentated at the 2nd International Glycoproteinosis Meeting in Ann Arbor, MI, USA. 2007 (abstract).
23. Krivit W. Stem cell bone marrow transplantation in patients with metabolic storage diseases. Adv Pediatr. 2002; 49: 359-378.
24. Lee WC, Tsoi YK, Troendle FJ, DeLucia MW, Ahmed Z, Dicky CA et al. Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy. FASEB J. 2007; 21: 2520-2527. (Pubitemid 47230681)
25. Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999; 281: 249-254. (Pubitemid 29058114)
26. Meikle PJ, Ranieri E, Simonsen H, Rozaklis T, Ramsay SL, Whitfield PD et al. Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy. Pediatrics. 2004; 114: 909-916. (Pubitemid 41529752)
27. Menon KP, Tieu PT, Neufeld EF. Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis I. Genomics. 1992; 14: 763-768.
28. Peters C, Balthazor M, Shapiro EG, King RJ, Kollman C, Hegland JD et al. Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood. 1996; 87: 4894-4902. (Pubitemid 26162394)
29. Rudich Z, Peng P, Dunn E, McCartney C. Stability of clonidine in clonidine-hydromorphone mixture from implanted intrathecal infusion pumps in chronic pain patients. J Pain Symptom Manage. 2004; 28: 599-602. (Pubitemid 39626105)
30. Scheinberg A, O'Flaherty S, Chaseling R, Dexter M. Continuous intrathecal baclofen infusion for children with cerebral palsy: a pilot study. J Paediatr Child Health. 2001; 37: 283-288. (Pubitemid 32619847)
31. Schiffmann R, Kopp JB, Austin HA 3rd, Sabnis S, Moore DF, Weibel T et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA. 2001; 285: 2743-2749. (Pubitemid 32525371)
32. Sivakumur P, Wraith JE. Bone marrow transplantation in mucopolysaccharidosis Type IIIA: a comparison of an early treated patient with his untreated sibling. J Inherit Metab Dis. 1999; 22: 849-850. (Pubitemid 29429948)
33. Staba SL, Escolar ML, Poe M, Kim Y, Martin PL, Szabolcs P et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med. 2004; 350: 1960-1969. (Pubitemid 38580199)
34. Tanaka K, Webster HD. Effects of psychosine (galactosylsphingosine) on the survival and the fine structure of cultured Schwann cells. J Neuropathol Exp Neurol. 1993; 52: 490-498. (Pubitemid 23269197)
35. Vogler C, Levy B, Grubb JH, Galvin N, Tan Y, Kakkis E et al. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA. 2005; 102: 14777-14782. (Pubitemid 41457132)
36. Wang J, Lozier J, Johnson G, Kirshner S, Verthelyi D, Pariser A et al. Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment. Nat Biotechnol. 2008; 26: 901-908.
37. Wraith JE. Advances in the treatment of lysosomal storage disease. Dev Med Child Neurol. 2001; 43: 639-646. (Pubitemid 32842539)
38. Yogalingam G, Pollard T, Gliddon B, Jolly RD, Hopwood JJ. Identification of a mutation causing mucopolysaccharidosis Type IIIA in New Zealand Huntaway dogs. Genomics. 2002; 79: 150-153. (Pubitemid 34124017)